1. Inicio
  2. Publicaciones
  3. Survival outcomes from the QUAZAR AML-001 trial with oral azacitidine (Oral-AZA) for patients with acute myeloid leukemia (AML) in remission by disease subtype, cytogenetic risk, and NPM1 mutation status at diagnosis (Dx)

Survival outcomes from the QUAZAR AML-001 trial with oral azacitidine (Oral-AZA) for patients with acute myeloid leukemia (AML) in remission by disease subtype, cytogenetic risk, and NPM1 mutation status at diagnosis (Dx)

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Pfeilstoecker, Michael
  • Doehner, Hartmut
  • Wei, Andrew
  • Roboz, Gail
  • Thol, Felicitas
  • La Torre, Ignazia
  • Skikne, Barry
  • See-Zepeda, Wendy
  • Ugidos, Manuel
  • Risueno, Alberto
  • Beach, C. L.
  • Menezes, Daniel

Grupos

Abstract

Abstract no disponible

Datos de la publicación

ISSN/ISSNe:
2296-5270, 2296-5262

Oncology Research and Treatment  KARGER

Tipo:
Meeting Abstract
Páginas:
141-141
DOI:
Factor de Impacto:
0,624 SCImago ℠
Cuartil:
Q2 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones

Filiaciones no disponibles

Campos de Estudio

Compartir